Negative Results: Relaxin ® Clinical Trials for Scleroderma
Phase III Relaxin Trial Did Not Reach Primary Endpoint.
Relaxin is of no value for the treatment of scleroderma.
"Scleroderma has again proven to be an extremely difficult disease for which to develop a therapeutic treatment." Connetics 10-8-00.
Scleroderma Research Registries. ISN.
Scleroderma Treatments & Clinical Trials. ISN.
Ineffective or Unproven Treatments for Scleroderma. ISN.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA